


*Randomized trial of vaginal
brachytherapy vs observation for
high-intermediate risk endometrial
carcinoma*

PORTEC-4



PORTEC-4 design

- *HIR endometrial carcinoma*
- *21 Gy in 3 fractions vs 15 Gy in 3 fractions*
- *Vaginal brachytherapy vs no further treatment*



PORTEC-4 accrual

- Accrual too slow
 - Patients prefer treatment esp after information
 - Current number: 50 / 500
- GCIG groups to participate:
 - MaNGO Italy – initiation phase
 - NCRI UK – CRUK endorsement
 - GOG US – final review

➤ Trial not feasible with current design

Major changes planned

- Dutch Cancer Society approval requested for major changes
- Molecular vs standard indications for no adjuvant vs brachy vs EBRT
- Protocol submission date 22-9-15
- PORTEC-3 and PORTEC-4 Investigator's update meeting: Friday May 29, State II, 4.00-4.30 pm